Navidea Biopharmaceuticals, Inc.
NAVB · OTC
9/30/2023 | 6/30/2023 | 3/31/2023 | 12/31/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | -0.00 | 0.02 | 0.01 |
| FCF Yield | -115.17% | 104.21% | -20.75% | -36.85% |
| EV / EBITDA | -3.00 | 0.15 | -9.09 | -2.26 |
| Quality | ||||
| ROIC | 208.90% | -190.99% | 37.10% | 63.87% |
| Gross Margin | 0.00% | 0.00% | 0.00% | -8,102.62% |
| Cash Conversion Ratio | 1.06 | 0.78 | 1.17 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | -90.45% | -76.30% | -65.57% | -61.17% |
| Free Cash Flow Growth | -321.95% | 362.56% | 29.68% | -29.34% |
| Safety | ||||
| Net Debt / EBITDA | 1.24 | 2.00 | -1.93 | -0.14 |
| Interest Coverage | -20.79 | 0.00 | -9.20 | -13.02 |
| Efficiency | ||||
| Inventory Turnover | 0.08 | 0.08 | 0.00 | 0.12 |
| Cash Conversion Cycle | -4,021.37 | -3,827.40 | 0.00 | -2,956.20 |